Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Park R, Li J, Slebos RJC, Chaudhary R, et al. Oral Oncol 2024;154:106866.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Park R, Li J, Slebos RJC, Chaudhary R, et al. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol 2024;154:106866.
PMID: 38820888